Gene therapy: Bpifrance participates in the initial public offering of Gensight

Bpifrance invests €14.5mn in Gensight Biologics on the occasion of its initial public offering on Euronext Paris (1), which allows the company to finance its development on the market of the orphan hereditary illnesses of the retina and of the central nervous system.

EnterpriseResearch and development

Image de la vidéo de présentation de Gensight
The funds raised by Gensight Biologics will finance clinical trials for its main drug candidate (GS010) in treating Leber’s Hereditary Optic Neuropathy (LHON). It is the first stock-exchange listing for a gene-therapy company in Europe.


Bpifrance Large Venture is taking part in the operation together with historic investors(2) that include Fonds Biothérapies innovantes et maladies rares (FBIMR – Fund for Innovative Biotherapies and Rare Diseases), managed by Bpifrance and subscribed by AFM-Téléthon and Fonds national d’amorçage (FNA – National Seed-Stage Fund) as part of the Programme d’investissements d’avenir (PIA – Programme of Investments for the Future).

See Gensight Biologics’ video presentation

In 2015, Bpifrance, the PIA as an operator, allocated €18.5mn to the Sight Again collaborative project. The project was developed by GenSight Biologics, Pixium Vision, and Fondation Voir et Entendre (See and Hear Foundation); its ambition is to restore sight to patients suffering from retinitis pigmentosa at different stages.


(1) ISIN Code: FR0013183985, mnemonic code: SIGHT.

(2) Novartis, Abingworth, Versant, Vitavest, Fidelity, Sphera, Jennison, Healthcap, and Perceptive.


Haut de page